NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Phone+1-203-9376137
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees7
OptionableOptionable
NanoViricides (NYSEAMERICAN:NNVC) Frequently Asked Questions
What is NanoViricides' stock symbol?
NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."
How were NanoViricides' earnings last quarter?
NanoViricides Inc (NYSEAMERICAN:NNVC) released its earnings results on Monday, November, 26th. The company reported ($0.03) EPS for the quarter. View NanoViricides' Earnings History.
When is NanoViricides' next earnings date?
Has NanoViricides been receiving favorable news coverage?
Press coverage about NNVC stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NanoViricides earned a news impact score of 0.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are some of NanoViricides' key competitors?
Some companies that are related to NanoViricides include Pharmaxis (PXS), Patrys (PAB), Avivagen (VIV), Antisense Therapeutics (ANP), China Pharma (CPHI), Allergy Therapeutics (AGY), Bayer (BAYN), Bayer (BAYN), BEXIMCO PHARMAC/S GDR REGS (BXP), Cathay International (CTI), Dechra Pharmaceuticals (DPH), Eco Animal Health Group (EAH), Futura Medical (FUM), Hutchison China MediTech (HCM) and N4 Pharma (N4P).
Who are NanoViricides' key executives?
NanoViricides' management team includes the folowing people:
- Dr. Anil R. Diwan, Chairman, Pres & Sec. (Age 60)
- Ms. Meeta R. Vyas SB, MBA, Chief Financial Officer (Age 60)
- Dr. Eugene Seymour, Chief Exec. Officer Emeritus (Age 78)
- Dr. Randall W. Barton Ph.D., Chief Scientific Officer & Chief Regulatory Officer (Age 72)
- Dr. Irach B. Taraporewala, Consultant & Director (Age 63)
How do I buy shares of NanoViricides?
Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NanoViricides' stock price today?
One share of NNVC stock can currently be purchased for approximately $0.43.
How big of a company is NanoViricides?
NanoViricides has a market capitalization of $29.83 million. NanoViricides employs 7 workers across the globe.
What is NanoViricides' official website?
How can I contact NanoViricides?
NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The company can be reached via phone at +1-203-9376137.
MarketBeat Community Rating for NanoViricides (NYSEAMERICAN NNVC)
MarketBeat's community ratings are surveys of what our community members think about NanoViricides and other stocks. Vote "Outperform" if you believe NNVC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NNVC will underperform the S&P 500 over the long term. You may vote once every thirty days.
